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CASE REPORT
First diagnosis of thrombotic 
thrombocytopenic purpura after SARS-CoV-2 
vaccine – case report
Bilgin Osmanodja1* , Adrian Schreiber1, Eva Schrezenmeier1,2 and Evelyn Seelow1 
Abstract 
Background: We report a case of a 25-year-old male patient, who developed acquired thrombotic thrombocyto-
penic purpura (aTTP) after receiving a first dose of mRNA-based SARS-CoV-2 vaccine Spikevax (mRNA-1273, Moderna 
Biotech, USA). While this is the first case in literature describing a case of aTTP after receiving the Spikevax vaccine, 
there are two other cases after mRNA-based Covid-19 vaccine and two after adenoviral SARS-CoV-2 vaccine.
Case presentation: The patient presented with persisting malaise, fever, headache, word-finding difficulties, nausea, 
vomiting, petechial bleeding, and hematuria 13 days after receiving a first dose of vaccination. Laboratory testing 
showed low platelet count, Coombs-negative hemolytic anemia, and mild acute kidney injury. We excluded vac-
cine induced immune thrombotic thrombocytopenia (VITT) as another important differential diagnosis and the final 
diagnosis was established after ADAMTS-13 (A Disintegrin And Metalloproteinase with a ThromboSpondin type 1 
motif, member 13) activity was found to be < 1% (reference range > 40%) and ADAMTS-13 antibodies being 72.2 IU/L 
(reference range < 12 IU/L).
We initiated empiric therapy of plasmapheresis and corticosteroids on admission and started caplacizumab the day 
after. The patient’s thrombocyte count normalized 3 days after admission, hemolysis and acute kidney injury resolved 
after 2 weeks. The patient received 2 doses of rituximab (1 g each) after the diagnosis of immune TTP was established. 
One month after the initial presentation, the patient is in good overall condition, but still receives daily caplacizumab 
due to ADAMTS-13 activity of < 1%.
Conclusions: Low platelet count after vaccination against SARS-CoV-2 has gained attraction after vaccine-induced 
immune thrombotic thrombocytopenia (VITT) has been described as a rare but severe complication of adenoviral-
based vaccines. Thrombotic thrombocytopenic purpura (TTP) is an important differential diagnosis, but there are 
only few reports of TTP following SARS-CoV-2 vaccination. Despite pathophysiological and clinical differences of both 
entities, diagnostic uncertainty can result in the acute setting, since they share main symptoms such as headache 
and neurological alterations in addition to thrombocytopenia. In difference to other cases reported, this patient 
developed first symptoms of TTP as early as 4 days after vaccination, which suggests that vaccination merely acted as 
trigger for occult TTP, instead of truly inducing an autoimmunological process.
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Background
Thrombotic thrombocytopenic purpura (TTP) is a 
rare thrombotic microangiopathy caused by decreased 
activity of ADAMTS-13 (A Disintegrin And Metal-
loproteinase with a ThromboSpondin type 1 motif, 
member 13), which leads to disseminated thrombus 
formation [1]. Most frequently, autoantibody formation 
against ADAMTS-13 leads to acquired TTP (aTTP), 
but in rare cases, mutations of the ADAMTS-13 gene 
can lead to congenital TTP as well [1, 2]. While natu-
ral disease course shows high mortality of > 90% due to 
ischemic kidney, brain and heart injury, therapy with 
plasma exchange, caplacizumab and immunosuppression 
decreased mortality to < 20% [3]. A variety of causative 
events, as well as triggers for a disease episode have been 
described in the literature, including vaccination against 
viral diseases.
We report the case of a 25-year-old male patient with 
unremarkable previous medical history, who developed 
a first episode of acquired thrombotic thrombocytopenic 
purpura (aTTP) after receiving a first dose of SARS-
CoV-2 vaccine Spikevax (mRNA-1273, Moderna Biotech, 
USA) [4]. While this is the first case in literature describ-
ing a case of aTTP after receiving the Spikevax vaccine, 
we found two other cases after mRNA-based SARS-
CoV-2 vaccine (Pfizer-BioNTech) and two after adenovi-
ral SARS-CoV-2 vaccine (AstraZeneca). Since aTTP and 
the more common adverse event of adenoviral SARS-
CoV-2 vaccines – vaccine induced immune thrombocy-
topenia (VITT) share common clinical and laboratory 
findings, distinguishing both is a challenge in the acute 
setting [5].
This case report follows CARE (Case Report) Guide-
lines, and a checklist is available with this article.
Case presentation
A 25-year-old male patient (175 cm, 107 kg) was admitted 
to our university hospital, after he presented in another 
emergency department 13 days after receiving a first 
dose of mRNA-based SARS-CoV-2 vaccination Spikevax 
(mRNA-1273, Moderna Biotech, USA). Chronologically, 
the patient’s symptoms developed as follows: immedi-
ately after vaccination he developed pain at the injection 
site. Additionally, he developed headache 2 days after the 
vaccination, and fever of up to 38.7 °C after 3 days. To 
ameliorate the fever, he took 500 mg of acetaminophen 
once. On day 4, he developed what he called a “rash” cov-
ering his abdomen and both legs. The same day, his urine 
color changed towards an “orange” tone and became 
foul smelling. During the following days, headache and 
fever waned, but progressive fatigue as well as exertional 
dyspnea developed. On the day of admission, he still had 
malaise, and woke up with a severe headache (numeric 
rating scale 7/10). That day, he vomited once with an 
empty stomach, and had persisting nausea the remaining 
day. Later in the other emergency department, he expe-
rienced word-finding difficulties, which he attributed to 
anxiety. He denied taking any other medication except 
for acetaminophen, drinking alcohol or using illicit drugs, 
which could have triggered the episode of aTTP. He had 
no family history for hematological, autoimmunological 
or kidney diseases.
On the initial examination, the only notable find-
ing was petechiae on both legs, which was the “rash” 
the patient described. The initial laboratory diagnostic 
showed Coombs-negative hemolytic anemia (Hb 7.4 g/
dL, LDH 999 U/L, schistocyte count 2.1%, haptoglobin 
< 0.1 g/L), low platelet count (29/nL), and elevated creati-
nine (1.5 mg/dL, eGFR 63.8 mL/min/1.73m2).
In summary, thrombotic microangiopathy was pre-
sent, and a presumptive diagnosis of aTTP was made. 
This was supported by high PLASMIC score of 6 points, 
predicting a high risk of 72% of ADAMTS-13 (A Disin-
tegrin And Metalloproteinase with a ThromboSpondin 
type 1 motif, member 13) deficiency. PLASMIC score 
was developed to identify those patients with low plate-
let count and signs of microangiopathic hemolytic ane-
mia (MAHA), who have low ADAMTS-13 activity < 10%. 
This is important, because those patient will benefit from 
immediate plasma exchange treatment [6].
Due to the combination of SARS-CoV-2 vaccine, head-
ache and thrombocytopenia, an important differential 
diagnosis was vaccine-induced immune thrombotic 
thrombocytopenia (VITT), which is described as a rare 
adverse event of adenoviral vector vaccines, but not 
mRNA-based vaccines against SARS-CoV-2. Since neu-
rological examination and head computer tomography 
were unremarkable, and no clinical signs of cerebral or 
peripheral thrombosis were present, we did not antico-
agulate the patient with argatroban, but only performed 
routine testing for heparin-induced thrombocytopenia 
(Milenia QuickLine HIT-Test, Milenia Biotech, Gießen, 
Germany), and sent out additional specimens for hep-
arine-induced platelet activation (HIPA) and platelet-
factor 4 enhanced platelet-activation test (PIPA), which 
are described elsewhere [5, 7]. All tests returned negative. 
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Additionally, cranial magnetic resonance imaging includ-
ing magnetic resonance angiography were performed 
to exclude cerebral sinus venous thrombosis (CSVT). 
Secondary reasons for TTP such as viral infections, 
autoimmune disorders, hematological or solid organ 
malignancies, as well as Shigatoxin-producing enterohe-
morrhagic E. coli as trigger for typical hemolytic uremic 
syndrome (HUS) were ruled out. Complement investi-
gations showed normal C3 and C4 levels and ruled out 
anti-factor H antibodies. Functional assays showed nor-
mal activity of the classical and the alternative pathway. 
A mild increase of soluble terminal complement activa-
tion fragments (C5b-9) levels indicated concomitant low 
grade complement activation. In conclusion, we classified 
this as autoimmune TTP.
After a suspected diagnosis of aTTP was made, the 
patient received daily plasma exchange with substitu-
tion of 2.5 L fresh frozen plasma and steroid pulse ther-
apy of 250 mg prednisolone daily for the first 3 days after 
admission. Additionally, caplacizumab (10 mg s.c. once 
daily) was started the second day after admission and 
continued until now (day 46). Plasma exchange was dis-
continued after 4 treatments since thrombocyte count 
normalized on day 3. Steroid therapy was tapered quickly 
to currently 6 mg daily. One week after admission, 
ADAMTS-13 activity returned highly suppressed (< 1%), 
with highly elevated ADAMTS-13 antibodies (72.2 IU/
mL) as well as decreased ADAMTS-13 antigen, which 
confirmed the suspected diagnosis. Since ADAMTS-13 
antibodies were detected, a diagnosis of autoimmune 
TTP was made, and immunosuppressive therapy with 
rituximab (1000 mg) was initiated 1 week after admission 
and repeated 2 weeks later. The patient was discharged 
8 days after initial admission and is in continuous fol-
low-up in our outpatient clinic. Hemolysis stopped after 
12 days, and creatinine stabilized at 1 mg/dl after 2 weeks 
of therapy. The main clinical events, diagnostic and ther-
apeutic measures are summarized in Fig.1. Additional 
medical therapy includes candesartan (4 mg b.i.d.) for 
arterial hypertension, Vitamin D (1000 IE once daily) and 
pantoprazole (20 mg once daily) for prophylaxis against 
osteoporosis and gastric ulcer as well as cotrimoxazole 
for prophylaxis against pneumocystis pneumonia. Over 
a month after initial admission, the patient is in good 
general health and most laboratory values normalized as 
shown in Table 1. Clinical signs of TTP such as petechiae 
dissolved and did not reappear. Since ADAMTS-13 activ-
ity is still < 1%, the patient is still receiving caplacizumab 
once daily [8]. Since ADAMTS-13 antigen is severely 
diminished, we suspect that the patient developed deplet-
ing ADAMTS-13 antibodies [1].
The patient reported full adherence to therapy, which 
is supported by normal thrombocyte count despite 
ADAMTS-13 activity < 1%. As a result of steroid treat-
ment, the patient developed steroid acne and as a 
suspected adverse event of cotrimoxazole treatment 
Fig. 1 Main events in chronological order. Thick black arrow – clinical event, thin black arrow – plasma exchange, red arrow – start steroids, green 
arrow – start caplacizumab, star – rituximab, blue line – LDH Level (U/L; NV 135-250), orange line – platelet count (/nL; NV 150-370), red dot – 
ADAMTS-13 antibodies (IU/mL; NV<12), LDH – Lactate Dehydrogenase; NV – Normal Values; Jun – June; Jul – July
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developed elevated liver enzymes. Since steroid therapy 
is tapered rapidly no specific therapy for steroid acne was 
started, but cotrimoxazole was paused after 2 weeks.
We recommended to withhold second vaccination 
against SARS-CoV-2 for two reasons. On the one hand, 
the patient has a low risk for severe course due to first 
successful vaccination and young age. On the other hand, 
due to current rituximab treatment, the response to vac-
cination will be severely reduced at the moment.
Patient perspective
Regarding the initial presentation, the patient described 
that he can neither fully remember the situation in the 
emergency department nor the fact that he wrote cryp-
tic text messages to his girlfriend or had word finding 
difficulties. Regarding the therapeutic measures, the 
patient reported that his “vitality” returned after the third 
plasma exchange treatment, but that those treatments 
were uncomfortable, since he developed chills. After dis-
charge, the patient recognized increased strength and 
insomnia, as well as acne, but no weight gain.
Initially, the patient was worried that he could develop 
further deterioration of kidney function including dialy-
sis. Now, he is confident that he will regain his normal 
health with medication and is not afraid between the 
appointments anymore.
Discussion and conclusions
To our knowledge, this is the first report of TTP after 
Spikevax vaccine, which is an important differential diag-
nosis in a patient with low platelet count after SARS-
CoV-2 vaccine. Still, there is some doubt, whether the 
autoimmunological process leading to aTTP itself was 
induced by vaccination. As the patient developed his first 
symptoms of aTTP as early as 4 days after vaccination, it 
is unlikely that formation of autoreactive B-cells, plasma 
cells and autoantibodies occurred that quickly. Usually, 
such process takes about 7–10 days and additional time 
for the clinical phenotype to develop is required as well. 
Instead, we argue that this patient most probably had 
occult undiagnosed aTTP and that the acute episode was 
then triggered by vaccination. This must be considered 
for other cases of aTTP after SARS-CoV-2 vaccination as 
well.
We treated our patient with steroids, plasma exchange, 
caplacizumab and rituximab according to the ISTH 
(International Society on Thrombosis and Haemostasis) 
Guidelines for Treatment of Thrombotic Thrombocyto-
penic Purpura from 2020 [9]. His response to treatment 
did not differ from other patients with aTTP.
In the literature, two case reports after adenoviral vec-
tor vaccines and two after mRNA-based vaccine were 
found, searching PubMed on July 27, 2021. For one case 
after mRNA-based vaccine, the first symptoms of bruis-
ing developed 2 weeks after the first vaccination, but 
diagnostic tests were performed 2 weeks after the second 
vaccination, when bruising increased [10]. The second 
case report described a patient with underlying human 
immunodeficiency virus (HIV) infection, who developed 
symptoms leading to TTP diagnosis 1 week after receiv-
ing the second dose [11]. For the two TTP cases after 
adenoviral vector vaccine, symptoms started 10 days 
and 37 after first vaccination, respectively [12, 13]. In 
all cases, only timing and absence of causes for second-
ary TTP led to the conclusion that TTP was induced by 
SARS-Cov-2 vaccination. There is no causal explanation 
Table 1 Important laboratory tests in chronological order
Laboratory Test Day 0 Day 1 Day 2 Day 3 Day 5 Day 7 Day 12 Day 20 Day 27 Day 33
Hemoglobin level (g/dL; NV 13.5–17) 7.40 7.20 6.60 7.30 8.10 9.10 11.1 13.1 14.6 14.0
Platelet count (/nL; NV 150–370) 29.00 23.00 114 151 341 498 443 240 253 316
Leukocyte count (/nL; NV 3.9–10.5) 15.08 11.60 16.42 11.15 21.37 25.57 9.75 10.42 10.35 10.0
Lymphocyte count (/nL; NV 1.1–4.5) 2.40 1.47 3.82 1.62 3.65 1.45 0.95
Reticulocyte count (/nL; NV 25–105) 233.1 233.8 262.4 277.2 424.9
Schistocyte count (%; NV < 1.0) 2.1%
LDH level (U/L; NV 135–250) 999 594 347 359 422 415 328 245 295 267
Haptoglobin level (g/L; NV 0.3–2.0) < 0.10 0.31 0.30 0.30 0.20 < 0.10 0.70 1.00 1.31 1.25
Bilirubin indirect (g/dL; < 0.75) 1.91 1.00 0.30 0.29 0.22 0.24 0.21
D-Dimers (mg/L; NV < 0.5) 2.95 4.30
CRP (mg/L; NV < 5.0) 9.50 7.00 6.20 6.90 2.30 5.60 0.90 0.50 2.90 0.70
Creatinine (mg/dL; NV 0.70–1.20) 1.50 1.28 1.33 1.24 1.14 1.01 0.96 0.98 0.86
ADAMTS-13 Antibodies (IU/mL; NV < 12) 72.2 36.7 111.6 > 92.0 73.2 49.7
ADAMTS-13 Antigen (%; NV > 40) 5 < 1 < 1 < 1 3 6
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for TTP induction to this point regarding molecular 
similarities between the two antigens ADAMTS-13 and 
SARS-CoV-2-spike (S) protein. Hence, it is conceivable 
that in some of the reported cases, vaccination was only 
triggering occult undiagnosed TTP, as we suspect it in 
our case.
In addition to such uncertainties, the acute presenta-
tion of patients with low platelet count after SARS-CoV-2 
vaccination poses a diagnostic challenge to the treating 
physicians. Even if VITT is an adverse event of adenovi-
ral vector vaccines, and TTP presents with thrombotic 
microangiopathy instead of CSVT, diagnosis can be 
challenging since both entities present with low plate-
let count and can present with neurological symptoms 
such as headache or focal deficits. Diagnostic tests such 
as ADAMTS-13 activity for TTP or HIPA and PIPA for 
VITT have long turnaround times, therefore it is impor-
tant to make a sound suspected diagnosis and ensure 
effective empiric therapy. Increased schistocyte count, 
Coombs-negative hemolytic anemia, acute non-severe 
kidney injury and PLASMIC score can point towards 
TTP, while CSVT on MRI as well as a history of adeno-
viral vector vaccine points towards VITT. With the num-
ber of case reports of TTP after SARS-CoV-2 vaccine 
increasing, progress needs to be made with respect to the 
causal relationship.
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